Figure 3
From: Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy – a case report
A – Kinetics of the prostate specific antigen (PSA). PSA values were determined in patients's blood before, during and after adoptive transfer therapy with TKD/IL-2-activated PBMNC. The arrows indicate the time points of cell re-infusions. B – Kinetics of the carcinoembryonic antigen (CEA). CEA values were determined in patient's blood before and during the adoptive transfer therapy with TKD/IL-2-activated PBMNC. The arrows indicate the time points of cell re-infusions. In 02/03 and in 06/05 primary tumor and anastomotic relapse was surgically removed. C – Kinetics of the carcinoembryonic antigen (CEA) after completion of the cell-based therapy. CEA values were determined in patient's blood after the adoptive transfer therapy with TKD/IL-2-activated PBMNC. In 10/06 a chemoembolisation of the liver metasases with Gemcitabine, Irinotecan, Epirubicin and Oxaliplatin was initiated.